Senseonics (NYSEAMERICAN:SENS) Raised to “Buy” at Zacks Investment Research

Share on StockTwits

Senseonics (NYSEAMERICAN:SENS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, Zacks.com reports. The firm currently has a $0.75 price target on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 8.70% from the company’s previous close.

According to Zacks, “Senseonics Holdings, Inc. is a medical technology company which focused on the design, development and commercialization of glucose monitoring systems. Senseonics Holdings, Inc. is based in Germantown, United States. “

Other equities research analysts have also recently issued reports about the stock. Guggenheim cut shares of Senseonics from a “buy” rating to a “neutral” rating in a report on Friday, March 13th. Canaccord Genuity decreased their price target on shares of Senseonics from $1.00 to $0.75 and set a “hold” rating for the company in a report on Friday, March 13th. Finally, BTIG Research cut shares of Senseonics from a “buy” rating to a “neutral” rating in a report on Friday, March 13th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Senseonics currently has an average rating of “Hold” and an average price target of $1.67.

SENS stock traded down $0.12 during mid-day trading on Thursday, reaching $0.69. 240,714 shares of the stock traded hands, compared to its average volume of 2,441,019. Senseonics has a 52 week low of $0.52 and a 52 week high of $2.66. The stock has a 50-day simple moving average of $1.07.

Senseonics (NYSEAMERICAN:SENS) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.02). The business had revenue of $9.00 million for the quarter, compared to the consensus estimate of $7.93 million.

Institutional investors and hedge funds have recently made changes to their positions in the company. Citigroup Inc. increased its holdings in shares of Senseonics by 130.4% during the fourth quarter. Citigroup Inc. now owns 38,446 shares of the company’s stock worth $35,000 after buying an additional 21,761 shares in the last quarter. Trust Co. of Oklahoma acquired a new stake in shares of Senseonics during the fourth quarter worth approximately $46,000. Palisade Capital Management LLC NJ increased its holdings in shares of Senseonics by 201.6% during the fourth quarter. Palisade Capital Management LLC NJ now owns 75,400 shares of the company’s stock worth $69,000 after buying an additional 50,400 shares in the last quarter. Spark Investment Management LLC acquired a new stake in shares of Senseonics during the fourth quarter worth approximately $75,000. Finally, Magnus Financial Group LLC acquired a new stake in shares of Senseonics during the fourth quarter worth approximately $79,000. 30.66% of the stock is owned by institutional investors and hedge funds.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Featured Story: Systematic Risk

Get a free copy of the Zacks research report on Senseonics (SENS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Senseonics (NYSEAMERICAN:SENS)

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.